NCT06004661 - Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 4, 2024

Primary Completion Date

June 5, 2026

Study Completion Date

August 4, 2026

Conditions

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventions

DRUG

AAA617

Administered intravenously once every cycles (1 cycle = 6 weeks)

DRUG

68Ga-PSMA-11

Single intravenous dose of approximately 150 MBq

Trial Locations (9)

RECRUITING

Mount Sinai Hosp School of Med, New York

RECRUITING

Novartis Investigative Site, Granada

RECRUITING

Novartis Investigative Site, Milan

RECRUITING

Novartis Investigative Site, El Palmar

RECRUITING

Novartis Investigative Site, Essen

RECRUITING

Novartis Investigative Site, Vandœuvre-lès-Nancy

RECRUITING

Novartis Investigative Site, Paris

RECRUITING

Novartis Investigative Site, Napoli

RECRUITING

Novartis Investigative Site, München